EICHOR
● Recruiting
A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1
Condition: Metastatic Adenocarcinoma of the Pancreas · Sponsor: Boryung Pharmaceutical Co., Ltd
About this study
The purpose of this clinical study is to compare and evaluate the pharmacokinetic characteristics and the safety between administration of BR2021 and BR2021-1 in patients with metastatic adenocarcinoma of the pancreas
This description comes directly from the study's public registry record.
Talk to the study team
Shin-young Oh · +82-2-708-8000 · syoh@boryung.co.kr
Always discuss trial participation with your own doctor first.
Locations (2)
| Asan Medical Center | Seoul, South Korea | Recruiting |
| The Catholic University of Korea Seoul St. Mary's Hospital | Seoul, South Korea | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06867497